AI-driven drug developer Insilico Medicine completed a Hong Kong IPO, marking a milestone for AI-first biotech listings. Separately, Shenzhen Edge Medical raised HKD1.19 billion (about US$154 million) in its HKEX IPO to fund surgical-robotics R&D and international expansion. These public offerings reflect renewed investor appetite for technology-led drug discovery and med‑tech hardware, and they illustrate how Asian capital markets are playing a larger role in life‑science financing and exits.